|
|
SHP2变构抑制剂的研究进展
|
Abstract:
蛋白酪氨酸磷酸酶在维持蛋白质酪氨酸磷酸化的稳态中起重要的调节作用。SHP2是首个被证实的致癌性蛋白酪氨酸磷酸酶，其信号失调与多种恶性肿瘤的发生发展密切相关。作为多条信号通路的交汇点，SHP2不仅影响肿瘤细胞的增殖、转移和侵袭等过程，并且还参与PD-1/PD-L1介导的肿瘤免疫逃逸，从多方面促进肿瘤的发生发展。因此SHP2被认为是一个理想的肿瘤干预靶标。然而，多年以来，人们为开发靶向SHP2的抗肿瘤药物付出了诸多努力，却收效甚微，为此SHP2曾一度被认为是“无药可及”的靶点。直至最近，以TNO155为代表的SHP2变构抑制剂相继进入临床开发，才为攻克这一极具挑战性的靶点带来希望。至今为止，已有13款SHP2变构抑制剂开展临床研究。本文简介SHP2的结构、功能及其与肿瘤的相关性，侧重综述近年来SHP2变构抑制剂的研发历程和临床试验的进展。
Protein tyrosine phosphatase plays an important role in maintaining protein tyrosine phosphoryla-tion homeostasis. SHP2 is the first confirmed carcinogenic protein tyrosine phosphatase, whose dysregulation is closely related to the occurrence and development of a variety of malignant tu-mors. As the intersection of multiple signaling pathways, SHP2 not only affects the proliferation, metastasis and invasion of tumor cells, but also participates in PD-1/PD-L1-mediated tumor im-mune escape, promoting the occurrence and development of tumors in many aspects. Therefore, SHP2 has been considered as an ideal target for cancer intervention. However, over the years, ef-forts to develop anti-tumor drugs targeting SHP2 have had little success. Hence, SHP2 was once con-sidered as an “undruggable” target. It is only recently that the clinical development of allosteric SHP2 inhibitors, represented by TNO155, has brought hope for tackling this challenging target. So far, there have been 13 candidates in clinical trials. This review briefly introduces the structure and functions of SHP2 and its correlation with tumors, and focuses on the development process and clinical trial progress of allosteric SHP2 inhibitors in recent years.
| [1] | Hunter, T. (1995) Protein Kinases and Phosphatases: The Yin and Yang of Protein phosphorylation and signaling. Cell, 80, 225-236. https://doi.org/10.1016/0092-8674(95)90405-0 |
| [2] | Singh, V., Ram, M., Kumar, R., et al. (2017) Phosphorylation: Implications in Cancer. Protein Journal, 36, 1-6.
https://doi.org/10.1007/s10930-017-9696-z |
| [3] | Attwood, M.M., Fabbro, D., Sokolov, A.V., et al. (2021) Trends in Kinase Drug Discovery: Targets, Indications and Inhibitor Design. Nature Reviews Drug Discovery, 20, 839-861. https://doi.org/10.1038/s41573-021-00252-y |
| [4] | Vainonen, J.P., Momeny, M. and Westermarck, J. (2021) Drug-gable Cancer Phosphatases. Science Translational Medicine, 13, eabe2967. https://doi.org/10.1126/scitranslmed.abe2967 |
| [5] | Barford, D., Neel, B.G. (1998) Revealing Mechanisms for SH2 Domain Mediated Regulation of the Protein Tyrosine Phosphatase SHP-2. Structure, 6, 249-254. https://doi.org/10.1016/S0969-2126(98)00027-6 |
| [6] | Song, Y., Zhao, M., Zhang, H., et al. (2022) Double-Edged Roles of Protein Tyrosine Phosphatase SHP2 in Cancer and Its Inhibitors in Clinical Trials. Pharmacology & Therapeu-tics, 230, Article ID: 107966.
https://doi.org/10.1016/j.pharmthera.2021.107966 |
| [7] | Chan, R.J. and Feng, G.S. (2007) PTPN11 Is the First Identified Proto-Oncogene That Encodes a Tyrosine Phosphatase. Blood, 109, 862-867. https://doi.org/10.1182/blood-2006-07-028829 |
| [8] | LaRochelle, J.R., Fodor, M., Vemulapalli, V., et al. (2018) Structural Reorganization of SHP2 by Oncogenic Mutations and Implications for Oncoprotein Resistance to Allosteric Inhibition. Nature Communications, 9, Article No. 4508.
https://doi.org/10.1038/s41467-018-06823-9 |
| [9] | Xu, R., Yu, Y., Zheng, S., et al. (2005) Overexpression of Shp2 Tyrosine Phosphatase Is Implicated in Leukemogenesis in Adult Human Leukemia. Blood, 106, 3142-3149. https://doi.org/10.1182/blood-2004-10-4057 |
| [10] | Nichols, R.J., Haderk, F., Stahlhut, C., et al. (2018) RAS nucleo-tide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1- and RAS-Driven Cancers. Nature Cell Biology, 20, 1064-1073.
https://doi.org/10.1038/s41556-018-0169-1 |
| [11] | Bunda, S., Burrell, K., Heir, P., et al. (2015) Inhibition of SHP2-Mediated Dephosphorylation of Ras Suppresses Oncogenesis. Nature Communications, 6, Article No. 8859. https://doi.org/10.1038/ncomms9859 |
| [12] | Hanafusa, H., Torii, S., Yasunaga, T., et al. (2004) Shp2, An SH2-Containing Protein-Tyrosine Phosphatase, Positively Regulates Receptor Tyrosine Kinase Signaling by Dephosphorylating and Inactivating the Inhibitor Sprouty. Journal of Biological Chemistry, 279, 22992-22995. https://doi.org/10.1074/jbc.M312498200 |
| [13] | Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., et al. (2012) Programmed Cell Death 1 Forms Negative Costimulatory Microclusters That Directly Inhibit T Cell Receptor Signaling by Recruiting Phosphatase SHP2. Journal of Experimental Medicine, 209, 1201-1217. https://doi.org/10.1084/jem.20112741 |
| [14] | Scott, L.M., Lawrence, H.R., Sebti, S.M., et al. (2010) Targeting Pro-tein Tyrosine Phosphatases for Anticancer Drug Discovery. Current Pharmaceutical Design, 16, 1843-1862. https://doi.org/10.2174/138161210791209027 |
| [15] | Garcia Fortanet, J., Chen, C.H., Chen, Y.N., et al. (2016) Allo-steric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. Journal of Medicinal Chemistry, 59, 7773-7782.
https://doi.org/10.1021/acs.jmedchem.6b00680 |
| [16] | Chen, Y.N., LaMarche, M.J., Chan, H.M., et al. (2016) Allo-steric Inhibition of SHP2 Phosphatase Inhibits Cancers Driven by Receptor Tyrosine Kinases. Nature, 535, 148-152. https://doi.org/10.1038/nature18621 |
| [17] | Zhao, M., Guo, W., Wu, Y., et al. (2019) SHP2 Inhibition Triggers An-ti-Tumor Immunity and Synergizes with PD-1 Blockade. Acta Pharmaceutica Sinica, B, 9, 304-315. https://doi.org/10.1016/j.apsb.2018.08.009 |
| [18] | LaMarche, M.J., Acker, M., Argintaru, A., et al. (2020) Identifica-tion of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 63, 13578-13594.
https://doi.org/10.1021/acs.jmedchem.0c01170 |
| [19] | Brana, I., Shapiro, G., Johnson, M., et al. (2021) Initial Results from a Dose Finding Study of TNO155, a SHP2 Inhibitor, in Adults with Advanced Solid Tumors. Journal of Clinical Oncology, 39, 3005.
https://doi.org/10.1200/JCO.2021.39.15_suppl.3005 |
| [20] | Bagdanoff, J.T., Chen, Z., Acker, M., et al. (2019) Op-timization of Fused Bicyclic Allosteric SHP2 Inhibitors. Journal of Medicinal Chemistry, 62, 1781-1792. https://doi.org/10.1021/acs.jmedchem.8b01725 |
| [21] | Sarver, P., Acker, M., Bagdanoff, J.T., et al. (2019) 6-Amino-3-Methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors. Journal of Medicinal Chemistry, 62, 1793-1802.
https://doi.org/10.1021/acs.jmedchem.8b01726 |
| [22] | Koltun, E.S. (2020) Discovery and Development of Allosteric Inhibitors of SHP2.
https://www.revmed.com/media/discovery-and-development-allosteric-inhibitors-shp2 |
| [23] | Koczywas, M., Haura, E., Janne, P., et al. (2021) Anti-Tumor Activity and Tolerability of the SHP2 Inhibitor RMC-4630 as a Single Agent in Pa-tients with RAS-Addicted Solid Cancers. Cancer Research, 81, LB001.
https://doi.org/10.1158/1538-7445.AM2021-LB001 https://www.revmed.com/media/anti-tumor-activity-and-tolerability-shp2-inhibitor-rmc-4630-single-agent-patients-ras |
| [24] | Czako, B., Sun, Y., McAfoos, T., Cross, J.B., Leonard, P.G., Burke, J.P., Burke, J.P., et al. (2021) Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor. Journal of Medicinal Chemistry, 64, 15141-15169. https://doi.org/10.1021/acs.jmedchem.1c01132 |
| [25] | Fodor, M., Price, E., Wang, P., et al. (2018) Dual Allosteric Inhibition of SHP2 Phosphatase. ACS Chemical Biology, 13, 647-656. https://doi.org/10.1021/acschembio.7b00980 |
| [26] | Wu, X., Xu, G., Li, X., et al. (2019) Small Molecule Inhibitor That Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2. Journal of Medicinal Chemistry, 62, 1125-1137.
https://doi.org/10.1021/acs.jmedchem.8b00513 |
| [27] | Marsh-Armstrong, B., Fajnzylber, J.M., Korntner, S., et al. (2018) The Allosteric Site on SHP2’s Protein Tyrosine Phosphatase Domain Is Targetable with Druglike Small Mole-cules. ACS Omega, 3, 15763-15770.
https://doi.org/10.1021/acsomega.8b02200 |
| [28] | Xie, J., Si, X., Gu, S., et al. (2017) Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment. Journal of Medicinal Chemistry, 60, 10205-10219. https://doi.org/10.1021/acs.jmedchem.7b01520 |
| [29] | Pádua, R.A.P., Sun, Y., Marko, I., et al. (2018) Mechanism of Activating Mutations and Allosteric Drug Inhibition of the Phosphatase SHP2. Nature Communications, 9, Article No. 4507. https://doi.org/10.1038/s41467-018-06814-w |
